nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimecrolimus—CYP3A4—Tamoxifen—pancreatic cancer	0.0212	0.24	CbGbCtD
Pimecrolimus—CYP3A4—Erlotinib—pancreatic cancer	0.018	0.204	CbGbCtD
Pimecrolimus—CYP3A4—Irinotecan—pancreatic cancer	0.0163	0.185	CbGbCtD
Pimecrolimus—CYP3A4—Docetaxel—pancreatic cancer	0.0119	0.135	CbGbCtD
Pimecrolimus—CYP3A4—Sunitinib—pancreatic cancer	0.0119	0.135	CbGbCtD
Pimecrolimus—CYP3A4—Doxorubicin—pancreatic cancer	0.00888	0.101	CbGbCtD
Pimecrolimus—Constipation—Erlotinib—pancreatic cancer	0.000846	0.00176	CcSEcCtD
Pimecrolimus—Pain—Erlotinib—pancreatic cancer	0.000846	0.00176	CcSEcCtD
Pimecrolimus—Erythema—Gemcitabine—pancreatic cancer	0.000842	0.00175	CcSEcCtD
Pimecrolimus—Nervous system disorder—Sunitinib—pancreatic cancer	0.00084	0.00174	CcSEcCtD
Pimecrolimus—Back pain—Irinotecan—pancreatic cancer	0.000836	0.00174	CcSEcCtD
Pimecrolimus—Skin disorder—Sunitinib—pancreatic cancer	0.000832	0.00173	CcSEcCtD
Pimecrolimus—Influenza like illness—Doxorubicin—pancreatic cancer	0.000829	0.00172	CcSEcCtD
Pimecrolimus—Erythema—Fluorouracil—pancreatic cancer	0.000828	0.00172	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Tamoxifen—pancreatic cancer	0.000818	0.0017	CcSEcCtD
Pimecrolimus—Back pain—Gemcitabine—pancreatic cancer	0.000815	0.00169	CcSEcCtD
Pimecrolimus—Skin exfoliation—Doxorubicin—pancreatic cancer	0.000815	0.00169	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Erlotinib—pancreatic cancer	0.000809	0.00168	CcSEcCtD
Pimecrolimus—Urticaria—Tamoxifen—pancreatic cancer	0.000795	0.00165	CcSEcCtD
Pimecrolimus—Abdominal pain—Tamoxifen—pancreatic cancer	0.000791	0.00164	CcSEcCtD
Pimecrolimus—Abdominal pain—Erlotinib—pancreatic cancer	0.000782	0.00162	CcSEcCtD
Pimecrolimus—Body temperature increased—Erlotinib—pancreatic cancer	0.000782	0.00162	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Sunitinib—pancreatic cancer	0.000781	0.00162	CcSEcCtD
Pimecrolimus—Pneumonia—Docetaxel—pancreatic cancer	0.000769	0.0016	CcSEcCtD
Pimecrolimus—Paraesthesia—Sunitinib—pancreatic cancer	0.000769	0.0016	CcSEcCtD
Pimecrolimus—Infestation NOS—Docetaxel—pancreatic cancer	0.000765	0.00159	CcSEcCtD
Pimecrolimus—Infestation—Docetaxel—pancreatic cancer	0.000765	0.00159	CcSEcCtD
Pimecrolimus—Dyspnoea—Sunitinib—pancreatic cancer	0.000764	0.00159	CcSEcCtD
Pimecrolimus—Cough—Irinotecan—pancreatic cancer	0.000755	0.00157	CcSEcCtD
Pimecrolimus—Conjunctivitis—Docetaxel—pancreatic cancer	0.000744	0.00154	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.00074	0.00154	CcSEcCtD
Pimecrolimus—Hypersensitivity—Tamoxifen—pancreatic cancer	0.000737	0.00153	CcSEcCtD
Pimecrolimus—Cough—Gemcitabine—pancreatic cancer	0.000735	0.00153	CcSEcCtD
Pimecrolimus—Pain—Sunitinib—pancreatic cancer	0.000733	0.00152	CcSEcCtD
Pimecrolimus—Constipation—Sunitinib—pancreatic cancer	0.000733	0.00152	CcSEcCtD
Pimecrolimus—Epistaxis—Docetaxel—pancreatic cancer	0.000722	0.0015	CcSEcCtD
Pimecrolimus—Arthralgia—Gemcitabine—pancreatic cancer	0.000717	0.00149	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—pancreatic cancer	0.000712	0.00148	CcSEcCtD
Pimecrolimus—Dermatitis exfoliative—Epirubicin—pancreatic cancer	0.00071	0.00147	CcSEcCtD
Pimecrolimus—Pruritus—Tamoxifen—pancreatic cancer	0.000708	0.00147	CcSEcCtD
Pimecrolimus—Oedema—Irinotecan—pancreatic cancer	0.000706	0.00146	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Irinotecan—pancreatic cancer	0.000706	0.00146	CcSEcCtD
Pimecrolimus—Infection—Irinotecan—pancreatic cancer	0.000701	0.00146	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Sunitinib—pancreatic cancer	0.000701	0.00145	CcSEcCtD
Pimecrolimus—Pruritus—Erlotinib—pancreatic cancer	0.0007	0.00145	CcSEcCtD
Pimecrolimus—Nervous system disorder—Irinotecan—pancreatic cancer	0.000692	0.00144	CcSEcCtD
Pimecrolimus—Rhinitis—Docetaxel—pancreatic cancer	0.000688	0.00143	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Gemcitabine—pancreatic cancer	0.000687	0.00143	CcSEcCtD
Pimecrolimus—Oedema—Gemcitabine—pancreatic cancer	0.000687	0.00143	CcSEcCtD
Pimecrolimus—Diarrhoea—Tamoxifen—pancreatic cancer	0.000684	0.00142	CcSEcCtD
Pimecrolimus—Infection—Gemcitabine—pancreatic cancer	0.000683	0.00142	CcSEcCtD
Pimecrolimus—Pharyngitis—Docetaxel—pancreatic cancer	0.000682	0.00141	CcSEcCtD
Pimecrolimus—Abdominal pain—Sunitinib—pancreatic cancer	0.000677	0.00141	CcSEcCtD
Pimecrolimus—Body temperature increased—Sunitinib—pancreatic cancer	0.000677	0.00141	CcSEcCtD
Pimecrolimus—Diarrhoea—Erlotinib—pancreatic cancer	0.000677	0.00141	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Fluorouracil—pancreatic cancer	0.000676	0.0014	CcSEcCtD
Pimecrolimus—Oedema—Fluorouracil—pancreatic cancer	0.000676	0.0014	CcSEcCtD
Pimecrolimus—Nervous system disorder—Gemcitabine—pancreatic cancer	0.000674	0.0014	CcSEcCtD
Pimecrolimus—Infection—Fluorouracil—pancreatic cancer	0.000672	0.00139	CcSEcCtD
Pimecrolimus—Skin disorder—Gemcitabine—pancreatic cancer	0.000668	0.00139	CcSEcCtD
Pimecrolimus—Nervous system disorder—Fluorouracil—pancreatic cancer	0.000663	0.00138	CcSEcCtD
Pimecrolimus—Dermatitis exfoliative—Doxorubicin—pancreatic cancer	0.000657	0.00136	CcSEcCtD
Pimecrolimus—Face oedema—Epirubicin—pancreatic cancer	0.000646	0.00134	CcSEcCtD
Pimecrolimus—Eye disorder—Docetaxel—pancreatic cancer	0.000642	0.00133	CcSEcCtD
Pimecrolimus—Flushing—Docetaxel—pancreatic cancer	0.000637	0.00132	CcSEcCtD
Pimecrolimus—Vomiting—Tamoxifen—pancreatic cancer	0.000636	0.00132	CcSEcCtD
Pimecrolimus—Paraesthesia—Irinotecan—pancreatic cancer	0.000634	0.00132	CcSEcCtD
Pimecrolimus—Hypersensitivity—Sunitinib—pancreatic cancer	0.000631	0.00131	CcSEcCtD
Pimecrolimus—Rash—Tamoxifen—pancreatic cancer	0.000631	0.00131	CcSEcCtD
Pimecrolimus—Dermatitis—Tamoxifen—pancreatic cancer	0.00063	0.00131	CcSEcCtD
Pimecrolimus—Vomiting—Erlotinib—pancreatic cancer	0.000629	0.00131	CcSEcCtD
Pimecrolimus—Dyspnoea—Irinotecan—pancreatic cancer	0.000629	0.00131	CcSEcCtD
Pimecrolimus—Headache—Tamoxifen—pancreatic cancer	0.000627	0.0013	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	0.000626	0.0013	CcSEcCtD
Pimecrolimus—Rash—Erlotinib—pancreatic cancer	0.000624	0.0013	CcSEcCtD
Pimecrolimus—Dermatitis—Erlotinib—pancreatic cancer	0.000623	0.00129	CcSEcCtD
Pimecrolimus—Immune system disorder—Docetaxel—pancreatic cancer	0.00062	0.00129	CcSEcCtD
Pimecrolimus—Headache—Erlotinib—pancreatic cancer	0.00062	0.00129	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Docetaxel—pancreatic cancer	0.000619	0.00128	CcSEcCtD
Pimecrolimus—Paraesthesia—Gemcitabine—pancreatic cancer	0.000617	0.00128	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.000616	0.00128	CcSEcCtD
Pimecrolimus—Dyspnoea—Gemcitabine—pancreatic cancer	0.000613	0.00127	CcSEcCtD
Pimecrolimus—Abdominal pain upper—Epirubicin—pancreatic cancer	0.000611	0.00127	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.000609	0.00126	CcSEcCtD
Pimecrolimus—Paraesthesia—Fluorouracil—pancreatic cancer	0.000607	0.00126	CcSEcCtD
Pimecrolimus—Pruritus—Sunitinib—pancreatic cancer	0.000606	0.00126	CcSEcCtD
Pimecrolimus—Breast disorder—Epirubicin—pancreatic cancer	0.000605	0.00126	CcSEcCtD
Pimecrolimus—Constipation—Irinotecan—pancreatic cancer	0.000604	0.00125	CcSEcCtD
Pimecrolimus—Pain—Irinotecan—pancreatic cancer	0.000604	0.00125	CcSEcCtD
Pimecrolimus—Dyspnoea—Fluorouracil—pancreatic cancer	0.000603	0.00125	CcSEcCtD
Pimecrolimus—Nasopharyngitis—Epirubicin—pancreatic cancer	0.000599	0.00124	CcSEcCtD
Pimecrolimus—Face oedema—Doxorubicin—pancreatic cancer	0.000598	0.00124	CcSEcCtD
Pimecrolimus—Malnutrition—Docetaxel—pancreatic cancer	0.000598	0.00124	CcSEcCtD
Pimecrolimus—Erythema—Docetaxel—pancreatic cancer	0.000598	0.00124	CcSEcCtD
Pimecrolimus—Nausea—Tamoxifen—pancreatic cancer	0.000594	0.00123	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000594	0.00123	CcSEcCtD
Pimecrolimus—Pain—Gemcitabine—pancreatic cancer	0.000588	0.00122	CcSEcCtD
Pimecrolimus—Constipation—Gemcitabine—pancreatic cancer	0.000588	0.00122	CcSEcCtD
Pimecrolimus—Nausea—Erlotinib—pancreatic cancer	0.000588	0.00122	CcSEcCtD
Pimecrolimus—Diarrhoea—Sunitinib—pancreatic cancer	0.000586	0.00122	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000584	0.00121	CcSEcCtD
Pimecrolimus—Influenza—Epirubicin—pancreatic cancer	0.000579	0.0012	CcSEcCtD
Pimecrolimus—Asthma—Epirubicin—pancreatic cancer	0.000579	0.0012	CcSEcCtD
Pimecrolimus—Back pain—Docetaxel—pancreatic cancer	0.000578	0.0012	CcSEcCtD
Pimecrolimus—Pain—Fluorouracil—pancreatic cancer	0.000578	0.0012	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.000577	0.0012	CcSEcCtD
Pimecrolimus—Abdominal pain upper—Doxorubicin—pancreatic cancer	0.000566	0.00117	CcSEcCtD
Pimecrolimus—Breast disorder—Doxorubicin—pancreatic cancer	0.00056	0.00116	CcSEcCtD
Pimecrolimus—Abdominal pain—Irinotecan—pancreatic cancer	0.000558	0.00116	CcSEcCtD
Pimecrolimus—Body temperature increased—Irinotecan—pancreatic cancer	0.000558	0.00116	CcSEcCtD
Pimecrolimus—Bronchitis—Epirubicin—pancreatic cancer	0.000557	0.00116	CcSEcCtD
Pimecrolimus—Nasopharyngitis—Doxorubicin—pancreatic cancer	0.000554	0.00115	CcSEcCtD
Pimecrolimus—Vomiting—Sunitinib—pancreatic cancer	0.000545	0.00113	CcSEcCtD
Pimecrolimus—Body temperature increased—Gemcitabine—pancreatic cancer	0.000543	0.00113	CcSEcCtD
Pimecrolimus—Rash—Sunitinib—pancreatic cancer	0.00054	0.00112	CcSEcCtD
Pimecrolimus—Dermatitis—Sunitinib—pancreatic cancer	0.00054	0.00112	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Epirubicin—pancreatic cancer	0.000538	0.00112	CcSEcCtD
Pimecrolimus—Urticaria—Fluorouracil—pancreatic cancer	0.000537	0.00111	CcSEcCtD
Pimecrolimus—Headache—Sunitinib—pancreatic cancer	0.000537	0.00111	CcSEcCtD
Pimecrolimus—Influenza—Doxorubicin—pancreatic cancer	0.000535	0.00111	CcSEcCtD
Pimecrolimus—Asthma—Doxorubicin—pancreatic cancer	0.000535	0.00111	CcSEcCtD
Pimecrolimus—Body temperature increased—Fluorouracil—pancreatic cancer	0.000534	0.00111	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Epirubicin—pancreatic cancer	0.000528	0.0011	CcSEcCtD
Pimecrolimus—Cough—Docetaxel—pancreatic cancer	0.000522	0.00108	CcSEcCtD
Pimecrolimus—Hypersensitivity—Irinotecan—pancreatic cancer	0.00052	0.00108	CcSEcCtD
Pimecrolimus—Pneumonia—Epirubicin—pancreatic cancer	0.000519	0.00108	CcSEcCtD
Pimecrolimus—Infestation NOS—Epirubicin—pancreatic cancer	0.000516	0.00107	CcSEcCtD
Pimecrolimus—Infestation—Epirubicin—pancreatic cancer	0.000516	0.00107	CcSEcCtD
Pimecrolimus—Bronchitis—Doxorubicin—pancreatic cancer	0.000515	0.00107	CcSEcCtD
Pimecrolimus—Arthralgia—Docetaxel—pancreatic cancer	0.000509	0.00106	CcSEcCtD
Pimecrolimus—Nausea—Sunitinib—pancreatic cancer	0.000509	0.00106	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000505	0.00105	CcSEcCtD
Pimecrolimus—Conjunctivitis—Epirubicin—pancreatic cancer	0.000502	0.00104	CcSEcCtD
Pimecrolimus—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000498	0.00103	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	0.000498	0.00103	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Doxorubicin—pancreatic cancer	0.000489	0.00101	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Docetaxel—pancreatic cancer	0.000488	0.00101	CcSEcCtD
Pimecrolimus—Oedema—Docetaxel—pancreatic cancer	0.000488	0.00101	CcSEcCtD
Pimecrolimus—Epistaxis—Epirubicin—pancreatic cancer	0.000487	0.00101	CcSEcCtD
Pimecrolimus—Pruritus—Gemcitabine—pancreatic cancer	0.000486	0.00101	CcSEcCtD
Pimecrolimus—Infection—Docetaxel—pancreatic cancer	0.000485	0.00101	CcSEcCtD
Pimecrolimus—Sinusitis—Epirubicin—pancreatic cancer	0.000484	0.001	CcSEcCtD
Pimecrolimus—Diarrhoea—Irinotecan—pancreatic cancer	0.000483	0.001	CcSEcCtD
Pimecrolimus—Pneumonia—Doxorubicin—pancreatic cancer	0.00048	0.000997	CcSEcCtD
Pimecrolimus—Nervous system disorder—Docetaxel—pancreatic cancer	0.000478	0.000993	CcSEcCtD
Pimecrolimus—Pruritus—Fluorouracil—pancreatic cancer	0.000478	0.000993	CcSEcCtD
Pimecrolimus—Infestation NOS—Doxorubicin—pancreatic cancer	0.000477	0.000991	CcSEcCtD
Pimecrolimus—Infestation—Doxorubicin—pancreatic cancer	0.000477	0.000991	CcSEcCtD
Pimecrolimus—Skin disorder—Docetaxel—pancreatic cancer	0.000474	0.000984	CcSEcCtD
Pimecrolimus—Diarrhoea—Gemcitabine—pancreatic cancer	0.00047	0.000976	CcSEcCtD
Pimecrolimus—Rhinitis—Epirubicin—pancreatic cancer	0.000464	0.000964	CcSEcCtD
Pimecrolimus—Conjunctivitis—Doxorubicin—pancreatic cancer	0.000464	0.000963	CcSEcCtD
Pimecrolimus—Diarrhoea—Fluorouracil—pancreatic cancer	0.000462	0.00096	CcSEcCtD
Pimecrolimus—Pharyngitis—Epirubicin—pancreatic cancer	0.00046	0.000954	CcSEcCtD
Pimecrolimus—Epistaxis—Doxorubicin—pancreatic cancer	0.00045	0.000935	CcSEcCtD
Pimecrolimus—Vomiting—Irinotecan—pancreatic cancer	0.000449	0.000931	CcSEcCtD
Pimecrolimus—Sinusitis—Doxorubicin—pancreatic cancer	0.000448	0.00093	CcSEcCtD
Pimecrolimus—Rash—Irinotecan—pancreatic cancer	0.000445	0.000924	CcSEcCtD
Pimecrolimus—Dermatitis—Irinotecan—pancreatic cancer	0.000445	0.000923	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000444	0.000923	CcSEcCtD
Pimecrolimus—Headache—Irinotecan—pancreatic cancer	0.000442	0.000918	CcSEcCtD
Pimecrolimus—Paraesthesia—Docetaxel—pancreatic cancer	0.000438	0.000909	CcSEcCtD
Pimecrolimus—Vomiting—Gemcitabine—pancreatic cancer	0.000437	0.000907	CcSEcCtD
Pimecrolimus—Dyspnoea—Docetaxel—pancreatic cancer	0.000435	0.000903	CcSEcCtD
Pimecrolimus—Rash—Gemcitabine—pancreatic cancer	0.000433	0.0009	CcSEcCtD
Pimecrolimus—Dermatitis—Gemcitabine—pancreatic cancer	0.000433	0.000899	CcSEcCtD
Pimecrolimus—Eye disorder—Epirubicin—pancreatic cancer	0.000433	0.000898	CcSEcCtD
Pimecrolimus—Headache—Gemcitabine—pancreatic cancer	0.000431	0.000894	CcSEcCtD
Pimecrolimus—Flushing—Epirubicin—pancreatic cancer	0.00043	0.000892	CcSEcCtD
Pimecrolimus—Vomiting—Fluorouracil—pancreatic cancer	0.00043	0.000892	CcSEcCtD
Pimecrolimus—Rhinitis—Doxorubicin—pancreatic cancer	0.00043	0.000892	CcSEcCtD
Pimecrolimus—Rash—Fluorouracil—pancreatic cancer	0.000426	0.000885	CcSEcCtD
Pimecrolimus—Dermatitis—Fluorouracil—pancreatic cancer	0.000426	0.000884	CcSEcCtD
Pimecrolimus—Pharyngitis—Doxorubicin—pancreatic cancer	0.000425	0.000883	CcSEcCtD
Pimecrolimus—Headache—Fluorouracil—pancreatic cancer	0.000423	0.000879	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000421	0.000874	CcSEcCtD
Pimecrolimus—Nausea—Irinotecan—pancreatic cancer	0.000419	0.00087	CcSEcCtD
Pimecrolimus—Immune system disorder—Epirubicin—pancreatic cancer	0.000418	0.000868	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Epirubicin—pancreatic cancer	0.000417	0.000866	CcSEcCtD
Pimecrolimus—Pain—Docetaxel—pancreatic cancer	0.000417	0.000866	CcSEcCtD
Pimecrolimus—Constipation—Docetaxel—pancreatic cancer	0.000417	0.000866	CcSEcCtD
Pimecrolimus—Nausea—Gemcitabine—pancreatic cancer	0.000408	0.000848	CcSEcCtD
Pimecrolimus—Malnutrition—Epirubicin—pancreatic cancer	0.000403	0.000837	CcSEcCtD
Pimecrolimus—Erythema—Epirubicin—pancreatic cancer	0.000403	0.000837	CcSEcCtD
Pimecrolimus—Nausea—Fluorouracil—pancreatic cancer	0.000401	0.000833	CcSEcCtD
Pimecrolimus—Eye disorder—Doxorubicin—pancreatic cancer	0.000401	0.000831	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000399	0.000828	CcSEcCtD
Pimecrolimus—Flushing—Doxorubicin—pancreatic cancer	0.000398	0.000826	CcSEcCtD
Pimecrolimus—Back pain—Epirubicin—pancreatic cancer	0.00039	0.00081	CcSEcCtD
Pimecrolimus—Immune system disorder—Doxorubicin—pancreatic cancer	0.000387	0.000804	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.000386	0.000802	CcSEcCtD
Pimecrolimus—Abdominal pain—Docetaxel—pancreatic cancer	0.000386	0.000801	CcSEcCtD
Pimecrolimus—Body temperature increased—Docetaxel—pancreatic cancer	0.000386	0.000801	CcSEcCtD
Pimecrolimus—Erythema—Doxorubicin—pancreatic cancer	0.000373	0.000774	CcSEcCtD
Pimecrolimus—Malnutrition—Doxorubicin—pancreatic cancer	0.000373	0.000774	CcSEcCtD
Pimecrolimus—Back pain—Doxorubicin—pancreatic cancer	0.000361	0.000749	CcSEcCtD
Pimecrolimus—Hypersensitivity—Docetaxel—pancreatic cancer	0.000359	0.000746	CcSEcCtD
Pimecrolimus—Cough—Epirubicin—pancreatic cancer	0.000352	0.00073	CcSEcCtD
Pimecrolimus—Pruritus—Docetaxel—pancreatic cancer	0.000345	0.000716	CcSEcCtD
Pimecrolimus—Arthralgia—Epirubicin—pancreatic cancer	0.000343	0.000713	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.000341	0.000708	CcSEcCtD
Pimecrolimus—Diarrhoea—Docetaxel—pancreatic cancer	0.000334	0.000693	CcSEcCtD
Pimecrolimus—Oedema—Epirubicin—pancreatic cancer	0.000329	0.000683	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Epirubicin—pancreatic cancer	0.000329	0.000683	CcSEcCtD
Pimecrolimus—Infection—Epirubicin—pancreatic cancer	0.000327	0.000679	CcSEcCtD
Pimecrolimus—Cough—Doxorubicin—pancreatic cancer	0.000326	0.000676	CcSEcCtD
Pimecrolimus—Nervous system disorder—Epirubicin—pancreatic cancer	0.000323	0.00067	CcSEcCtD
Pimecrolimus—Skin disorder—Epirubicin—pancreatic cancer	0.00032	0.000663	CcSEcCtD
Pimecrolimus—Arthralgia—Doxorubicin—pancreatic cancer	0.000318	0.000659	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000315	0.000655	CcSEcCtD
Pimecrolimus—Vomiting—Docetaxel—pancreatic cancer	0.00031	0.000644	CcSEcCtD
Pimecrolimus—Rash—Docetaxel—pancreatic cancer	0.000308	0.000639	CcSEcCtD
Pimecrolimus—Dermatitis—Docetaxel—pancreatic cancer	0.000307	0.000638	CcSEcCtD
Pimecrolimus—Headache—Docetaxel—pancreatic cancer	0.000306	0.000634	CcSEcCtD
Pimecrolimus—Oedema—Doxorubicin—pancreatic cancer	0.000304	0.000632	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Doxorubicin—pancreatic cancer	0.000304	0.000632	CcSEcCtD
Pimecrolimus—Infection—Doxorubicin—pancreatic cancer	0.000302	0.000628	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.0003	0.000622	CcSEcCtD
Pimecrolimus—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000299	0.00062	CcSEcCtD
Pimecrolimus—Skin disorder—Doxorubicin—pancreatic cancer	0.000296	0.000614	CcSEcCtD
Pimecrolimus—Paraesthesia—Epirubicin—pancreatic cancer	0.000295	0.000613	CcSEcCtD
Pimecrolimus—Dyspnoea—Epirubicin—pancreatic cancer	0.000293	0.000609	CcSEcCtD
Pimecrolimus—Nausea—Docetaxel—pancreatic cancer	0.00029	0.000602	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000284	0.00059	CcSEcCtD
Pimecrolimus—Pain—Epirubicin—pancreatic cancer	0.000281	0.000584	CcSEcCtD
Pimecrolimus—Constipation—Epirubicin—pancreatic cancer	0.000281	0.000584	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.000277	0.000576	CcSEcCtD
Pimecrolimus—Paraesthesia—Doxorubicin—pancreatic cancer	0.000273	0.000568	CcSEcCtD
Pimecrolimus—Dyspnoea—Doxorubicin—pancreatic cancer	0.000271	0.000563	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000269	0.000559	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000263	0.000546	CcSEcCtD
Pimecrolimus—Urticaria—Epirubicin—pancreatic cancer	0.000261	0.000543	CcSEcCtD
Pimecrolimus—Constipation—Doxorubicin—pancreatic cancer	0.00026	0.00054	CcSEcCtD
Pimecrolimus—Pain—Doxorubicin—pancreatic cancer	0.00026	0.00054	CcSEcCtD
Pimecrolimus—Abdominal pain—Epirubicin—pancreatic cancer	0.00026	0.00054	CcSEcCtD
Pimecrolimus—Body temperature increased—Epirubicin—pancreatic cancer	0.00026	0.00054	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000249	0.000517	CcSEcCtD
Pimecrolimus—Hypersensitivity—Epirubicin—pancreatic cancer	0.000242	0.000503	CcSEcCtD
Pimecrolimus—Urticaria—Doxorubicin—pancreatic cancer	0.000242	0.000502	CcSEcCtD
Pimecrolimus—Abdominal pain—Doxorubicin—pancreatic cancer	0.000241	0.0005	CcSEcCtD
Pimecrolimus—Body temperature increased—Doxorubicin—pancreatic cancer	0.000241	0.0005	CcSEcCtD
Pimecrolimus—Pruritus—Epirubicin—pancreatic cancer	0.000233	0.000483	CcSEcCtD
Pimecrolimus—Diarrhoea—Epirubicin—pancreatic cancer	0.000225	0.000467	CcSEcCtD
Pimecrolimus—Hypersensitivity—Doxorubicin—pancreatic cancer	0.000224	0.000466	CcSEcCtD
Pimecrolimus—Pruritus—Doxorubicin—pancreatic cancer	0.000215	0.000447	CcSEcCtD
Pimecrolimus—Vomiting—Epirubicin—pancreatic cancer	0.000209	0.000434	CcSEcCtD
Pimecrolimus—Diarrhoea—Doxorubicin—pancreatic cancer	0.000208	0.000432	CcSEcCtD
Pimecrolimus—Rash—Epirubicin—pancreatic cancer	0.000207	0.000431	CcSEcCtD
Pimecrolimus—Dermatitis—Epirubicin—pancreatic cancer	0.000207	0.00043	CcSEcCtD
Pimecrolimus—Headache—Epirubicin—pancreatic cancer	0.000206	0.000428	CcSEcCtD
Pimecrolimus—Nausea—Epirubicin—pancreatic cancer	0.000195	0.000406	CcSEcCtD
Pimecrolimus—Vomiting—Doxorubicin—pancreatic cancer	0.000194	0.000402	CcSEcCtD
Pimecrolimus—Rash—Doxorubicin—pancreatic cancer	0.000192	0.000399	CcSEcCtD
Pimecrolimus—Dermatitis—Doxorubicin—pancreatic cancer	0.000192	0.000398	CcSEcCtD
Pimecrolimus—Headache—Doxorubicin—pancreatic cancer	0.000191	0.000396	CcSEcCtD
Pimecrolimus—Nausea—Doxorubicin—pancreatic cancer	0.000181	0.000375	CcSEcCtD
Pimecrolimus—MTOR—Signaling by NGF—PTEN—pancreatic cancer	0.000163	0.00038	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KRAS—pancreatic cancer	0.000163	0.000379	CbGpPWpGaD
Pimecrolimus—MTOR—BDNF signaling pathway—AKT1—pancreatic cancer	0.000163	0.000379	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—IAPP—pancreatic cancer	0.000163	0.000379	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—BCL2L1—pancreatic cancer	0.00016	0.000373	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—DTX4—pancreatic cancer	0.00016	0.000371	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—GLI1—pancreatic cancer	0.00016	0.000371	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—TERT—pancreatic cancer	0.00016	0.000371	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—TSC2—pancreatic cancer	0.000159	0.00037	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—GCG—pancreatic cancer	0.000159	0.000369	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—AKT1—pancreatic cancer	0.000159	0.000369	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—VEGFA—pancreatic cancer	0.000157	0.000366	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—AKT1—pancreatic cancer	0.000157	0.000365	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—PIK3CA—pancreatic cancer	0.000157	0.000364	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—HRAS—pancreatic cancer	0.000157	0.000364	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—HRAS—pancreatic cancer	0.000157	0.000364	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—pancreatic cancer	0.000157	0.000364	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—HSPA1B—pancreatic cancer	0.000156	0.000364	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—AKT1—pancreatic cancer	0.000156	0.000363	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—STAT3—pancreatic cancer	0.000156	0.000362	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NRP1—pancreatic cancer	0.000155	0.000361	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PPP2R5B—pancreatic cancer	0.000155	0.000361	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—HRAS—pancreatic cancer	0.000155	0.000361	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—HRAS—pancreatic cancer	0.000154	0.000357	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—HRAS—pancreatic cancer	0.000153	0.000356	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—TSC2—pancreatic cancer	0.000153	0.000356	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—HIF1A—pancreatic cancer	0.000153	0.000355	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—TSC2—pancreatic cancer	0.000152	0.000354	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—SRC—pancreatic cancer	0.000152	0.000352	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—AGTR1—pancreatic cancer	0.000151	0.000352	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—PIK3CA—pancreatic cancer	0.00015	0.000348	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin Signaling—AKT1—pancreatic cancer	0.00015	0.000348	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HEY2—pancreatic cancer	0.00015	0.000348	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—STK11—pancreatic cancer	0.000149	0.000347	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—APOE—pancreatic cancer	0.000149	0.000347	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—AKT1—pancreatic cancer	0.000149	0.000347	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—AKT1—pancreatic cancer	0.000148	0.000345	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—AKT1—pancreatic cancer	0.000148	0.000345	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—AKT1—pancreatic cancer	0.000148	0.000343	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—AKT1—pancreatic cancer	0.000147	0.000342	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—GAST—pancreatic cancer	0.000146	0.00034	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—STAT3—pancreatic cancer	0.000146	0.00034	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—NRAS—pancreatic cancer	0.000146	0.000339	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—NFKBIA—pancreatic cancer	0.000145	0.000338	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—HRAS—pancreatic cancer	0.000145	0.000337	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—pancreatic cancer	0.000145	0.000337	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD44—pancreatic cancer	0.000144	0.000335	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—JAG1—pancreatic cancer	0.00014	0.000325	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—NFKBIA—pancreatic cancer	0.00014	0.000324	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IFNA1—pancreatic cancer	0.00014	0.000324	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—EGF—pancreatic cancer	0.000139	0.000323	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—pancreatic cancer	0.000139	0.000322	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SCT—pancreatic cancer	0.000139	0.000322	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HEY1—pancreatic cancer	0.000139	0.000322	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—AKT1—pancreatic cancer	0.000138	0.000321	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—AKT1—pancreatic cancer	0.000138	0.000321	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—AKT1—pancreatic cancer	0.000138	0.000321	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—NOTCH1—pancreatic cancer	0.000138	0.00032	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—AKT1—pancreatic cancer	0.000137	0.000318	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—AKT1—pancreatic cancer	0.000136	0.000316	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—AKT1—pancreatic cancer	0.000135	0.000314	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—EGF—pancreatic cancer	0.000134	0.000311	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—EGF—pancreatic cancer	0.000133	0.000309	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CD44—pancreatic cancer	0.000133	0.000309	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—EGFR—pancreatic cancer	0.000133	0.000309	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCK—pancreatic cancer	0.000132	0.000307	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—HSPA1A—pancreatic cancer	0.000132	0.000307	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—SMAD4—pancreatic cancer	0.000131	0.000304	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IFNA2—pancreatic cancer	0.00013	0.000302	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CNR2—pancreatic cancer	0.000129	0.000299	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—GLP1R—pancreatic cancer	0.000129	0.000299	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—AKT1—pancreatic cancer	0.000128	0.000297	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—HES1—pancreatic cancer	0.000128	0.000297	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCKAR—pancreatic cancer	0.000127	0.000295	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—KRAS—pancreatic cancer	0.000125	0.000292	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CDH1—pancreatic cancer	0.000124	0.000289	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—PIK3CD—pancreatic cancer	0.000124	0.000288	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—JAG2—pancreatic cancer	0.000123	0.000286	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—pancreatic cancer	0.000122	0.000285	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MEN1—pancreatic cancer	0.000121	0.000282	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—TP53—pancreatic cancer	0.000119	0.000276	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—PIK3CD—pancreatic cancer	0.000119	0.000276	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PIK3CD—pancreatic cancer	0.000118	0.000275	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SHH—pancreatic cancer	0.000116	0.000269	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—PIK3CA—pancreatic cancer	0.000115	0.000268	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NOTCH4—pancreatic cancer	0.000115	0.000267	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IAPP—pancreatic cancer	0.000114	0.000265	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TERT—pancreatic cancer	0.000112	0.00026	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PTHLH—pancreatic cancer	0.00011	0.000255	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PTCH1—pancreatic cancer	0.00011	0.000255	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—PIK3CB—pancreatic cancer	0.000108	0.000251	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—HIF1A—pancreatic cancer	0.000107	0.000249	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TSC2—pancreatic cancer	0.000107	0.000248	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—HRAS—pancreatic cancer	0.000107	0.000248	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—SMAD4—pancreatic cancer	0.000105	0.000244	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—APOE—pancreatic cancer	0.000104	0.000243	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—PIK3CB—pancreatic cancer	0.000104	0.000241	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PIK3CB—pancreatic cancer	0.000103	0.00024	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—HES1—pancreatic cancer	0.000103	0.000238	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—KDR—pancreatic cancer	0.000102	0.000238	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PTGS2—pancreatic cancer	0.000102	0.000238	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SST—pancreatic cancer	0.0001	0.000233	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—JAG1—pancreatic cancer	9.8e-05	0.000228	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NOTCH3—pancreatic cancer	9.76e-05	0.000227	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NFKBIA—pancreatic cancer	9.73e-05	0.000226	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NOTCH1—pancreatic cancer	9.64e-05	0.000224	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CTNNB1—pancreatic cancer	9.56e-05	0.000222	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PIK3CG—pancreatic cancer	9.42e-05	0.000219	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—AKT1—pancreatic cancer	9.42e-05	0.000219	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—BCL2L1—pancreatic cancer	9.34e-05	0.000217	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—PTEN—pancreatic cancer	9.32e-05	0.000217	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—EGF—pancreatic cancer	9.32e-05	0.000217	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—TSC2—pancreatic cancer	9.28e-05	0.000216	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CNR1—pancreatic cancer	9.25e-05	0.000215	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CTNNB1—pancreatic cancer	9.14e-05	0.000213	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—TERT—pancreatic cancer	8.98e-05	0.000209	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—PTEN—pancreatic cancer	8.95e-05	0.000208	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—GCG—pancreatic cancer	8.93e-05	0.000208	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PTEN—pancreatic cancer	8.91e-05	0.000207	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—SRC—pancreatic cancer	8.64e-05	0.000201	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—HIF1A—pancreatic cancer	8.59e-05	0.0002	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—TSC2—pancreatic cancer	8.57e-05	0.000199	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AGTR1—pancreatic cancer	8.52e-05	0.000198	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—NFKBIA—pancreatic cancer	8.46e-05	0.000197	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—STK11—pancreatic cancer	8.4e-05	0.000195	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—APOE—pancreatic cancer	8.39e-05	0.000195	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—NRAS—pancreatic cancer	8.31e-05	0.000193	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—SRC—pancreatic cancer	8.3e-05	0.000193	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PIK3CD—pancreatic cancer	8.29e-05	0.000193	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—SRC—pancreatic cancer	8.26e-05	0.000192	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—EGF—pancreatic cancer	8.1e-05	0.000188	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—NRAS—pancreatic cancer	7.98e-05	0.000186	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—STAT3—pancreatic cancer	7.97e-05	0.000185	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—NRAS—pancreatic cancer	7.95e-05	0.000185	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NOTCH1—pancreatic cancer	7.74e-05	0.00018	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—EGFR—pancreatic cancer	7.58e-05	0.000176	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CDH1—pancreatic cancer	7.54e-05	0.000175	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—EGF—pancreatic cancer	7.48e-05	0.000174	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MYC—pancreatic cancer	7.41e-05	0.000172	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—TGFB1—pancreatic cancer	7.39e-05	0.000172	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SMAD4—pancreatic cancer	7.35e-05	0.000171	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—EGFR—pancreatic cancer	7.27e-05	0.000169	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—EGFR—pancreatic cancer	7.24e-05	0.000168	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PIK3CB—pancreatic cancer	7.22e-05	0.000168	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PIK3CD—pancreatic cancer	7.21e-05	0.000168	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HES1—pancreatic cancer	7.18e-05	0.000167	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—KRAS—pancreatic cancer	7.16e-05	0.000166	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CXCL8—pancreatic cancer	6.94e-05	0.000161	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—KRAS—pancreatic cancer	6.87e-05	0.00016	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—KRAS—pancreatic cancer	6.84e-05	0.000159	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PRSS1—pancreatic cancer	6.69e-05	0.000155	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PIK3CD—pancreatic cancer	6.65e-05	0.000155	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CASP3—pancreatic cancer	6.64e-05	0.000154	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—PIK3CA—pancreatic cancer	6.57e-05	0.000153	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CCND1—pancreatic cancer	6.47e-05	0.00015	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CTNNB1—pancreatic cancer	6.4e-05	0.000149	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—PIK3CA—pancreatic cancer	6.31e-05	0.000147	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TERT—pancreatic cancer	6.29e-05	0.000146	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PIK3CA—pancreatic cancer	6.29e-05	0.000146	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PIK3CB—pancreatic cancer	6.28e-05	0.000146	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MMP9—pancreatic cancer	6.28e-05	0.000146	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PTEN—pancreatic cancer	6.24e-05	0.000145	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—HRAS—pancreatic cancer	6.08e-05	0.000141	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HIF1A—pancreatic cancer	6.02e-05	0.00014	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TSC2—pancreatic cancer	6e-05	0.00014	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—APOE—pancreatic cancer	5.87e-05	0.000137	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—HRAS—pancreatic cancer	5.84e-05	0.000136	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—HRAS—pancreatic cancer	5.82e-05	0.000135	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PIK3CB—pancreatic cancer	5.8e-05	0.000135	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ARG2—pancreatic cancer	5.8e-05	0.000135	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—SRC—pancreatic cancer	5.79e-05	0.000135	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—KDR—pancreatic cancer	5.75e-05	0.000134	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PTGS2—pancreatic cancer	5.75e-05	0.000134	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—VEGFA—pancreatic cancer	5.64e-05	0.000131	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—STAT3—pancreatic cancer	5.58e-05	0.00013	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CTNNB1—pancreatic cancer	5.57e-05	0.000129	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NRAS—pancreatic cancer	5.57e-05	0.000129	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NFKBIA—pancreatic cancer	5.47e-05	0.000127	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PTEN—pancreatic cancer	5.43e-05	0.000126	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NOTCH1—pancreatic cancer	5.42e-05	0.000126	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—AKT1—pancreatic cancer	5.37e-05	0.000125	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PIK3CG—pancreatic cancer	5.3e-05	0.000123	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—EGF—pancreatic cancer	5.24e-05	0.000122	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MYC—pancreatic cancer	5.19e-05	0.000121	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TGFB1—pancreatic cancer	5.17e-05	0.00012	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—AKT1—pancreatic cancer	5.16e-05	0.00012	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CTNNB1—pancreatic cancer	5.14e-05	0.00012	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—AKT1—pancreatic cancer	5.14e-05	0.000119	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—EGFR—pancreatic cancer	5.07e-05	0.000118	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—TYMP—pancreatic cancer	5.07e-05	0.000118	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—SRC—pancreatic cancer	5.03e-05	0.000117	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PTEN—pancreatic cancer	5.01e-05	0.000116	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—STAT3—pancreatic cancer	4.85e-05	0.000113	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—NRAS—pancreatic cancer	4.84e-05	0.000113	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—KRAS—pancreatic cancer	4.79e-05	0.000111	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PIK3CD—pancreatic cancer	4.66e-05	0.000108	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—SRC—pancreatic cancer	4.65e-05	0.000108	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—STAT3—pancreatic cancer	4.48e-05	0.000104	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NRAS—pancreatic cancer	4.47e-05	0.000104	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—EGFR—pancreatic cancer	4.41e-05	0.000103	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PIK3CA—pancreatic cancer	4.4e-05	0.000102	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TP53—pancreatic cancer	4.26e-05	9.9e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—KRAS—pancreatic cancer	4.17e-05	9.69e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MYC—pancreatic cancer	4.16e-05	9.68e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—TGFB1—pancreatic cancer	4.15e-05	9.66e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GLP1R—pancreatic cancer	4.09e-05	9.5e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—EGFR—pancreatic cancer	4.07e-05	9.47e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—HRAS—pancreatic cancer	4.07e-05	9.47e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PIK3CB—pancreatic cancer	4.06e-05	9.44e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—DPYD—pancreatic cancer	4.02e-05	9.34e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CXCL8—pancreatic cancer	3.9e-05	9.07e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—KRAS—pancreatic cancer	3.85e-05	8.95e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PIK3CA—pancreatic cancer	3.83e-05	8.9e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	3.81e-05	8.87e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CASP3—pancreatic cancer	3.74e-05	8.68e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCND1—pancreatic cancer	3.64e-05	8.45e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CTNNB1—pancreatic cancer	3.6e-05	8.37e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—AKT1—pancreatic cancer	3.6e-05	8.36e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—HRAS—pancreatic cancer	3.54e-05	8.24e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PIK3CA—pancreatic cancer	3.54e-05	8.22e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MMP9—pancreatic cancer	3.53e-05	8.21e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PTEN—pancreatic cancer	3.51e-05	8.16e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—HRAS—pancreatic cancer	3.27e-05	7.6e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SRC—pancreatic cancer	3.25e-05	7.57e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—VEGFA—pancreatic cancer	3.17e-05	7.37e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—STAT3—pancreatic cancer	3.14e-05	7.3e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NRAS—pancreatic cancer	3.13e-05	7.28e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—AKT1—pancreatic cancer	3.13e-05	7.27e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CD44—pancreatic cancer	2.95e-05	6.87e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MYC—pancreatic cancer	2.92e-05	6.78e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TGFB1—pancreatic cancer	2.91e-05	6.76e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—AKT1—pancreatic cancer	2.89e-05	6.71e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—EGFR—pancreatic cancer	2.85e-05	6.63e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GCG—pancreatic cancer	2.83e-05	6.58e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—KRAS—pancreatic cancer	2.69e-05	6.26e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—STK11—pancreatic cancer	2.66e-05	6.19e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PIK3CA—pancreatic cancer	2.48e-05	5.76e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TP53—pancreatic cancer	2.4e-05	5.57e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—TYMS—pancreatic cancer	2.29e-05	5.32e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HRAS—pancreatic cancer	2.29e-05	5.32e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AKT1—pancreatic cancer	2.02e-05	4.7e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—APOE—pancreatic cancer	1.86e-05	4.33e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	1.68e-05	3.91e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PPARG—pancreatic cancer	1.62e-05	3.77e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	1.48e-05	3.44e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	1.29e-05	2.99e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PTGS2—pancreatic cancer	1.28e-05	2.97e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PTEN—pancreatic cancer	1.11e-05	2.59e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	7.85e-06	1.83e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—AKT1—pancreatic cancer	6.42e-06	1.49e-05	CbGpPWpGaD
